Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ...

On Monday, SK revealed that it will spend $260 million to construct its fifth production site in its home country, this one ...

Otsuka is once again on the PMCPA’s naughty list as the U.K. drug marketing regulatory body has for the second time this year ...